Ipca Laboratories (IPCALAB) Stock Overview
An integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for IPCALAB from our risk checks.
IPCALAB Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ipca Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,602.10 |
| 52 Week High | ₹1,678.30 |
| 52 Week Low | ₹1,251.60 |
| Beta | 0.072 |
| 1 Month Change | 7.18% |
| 3 Month Change | 10.50% |
| 1 Year Change | 9.73% |
| 3 Year Change | 134.07% |
| 5 Year Change | 58.05% |
| Change since IPO | 4,116.05% |
Recent News & Updates
Narrative Update • May 06
IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility
Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).Narrative Update • Apr 19
IPCALAB: Upcoming Results And Revised Assumptions Will Guide Earnings Visibility
Analysts have trimmed their fair value estimate for Ipca Laboratories slightly from about ₹1,416 to around ₹1,407, reflecting updated assumptions on future revenue growth, profit margins and a modestly lower future P/E multiple. What's in the News Board meeting scheduled on February 13, 2026, to consider and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).
Narrative Update • Apr 05
IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value
Analysts have kept their fair value estimate for Ipca Laboratories steady at ₹1,655, reflecting unchanged assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for February 13, 2026 to consider and record the standalone unaudited financial results for the third quarter ended December 31, 2025 (Key Developments).Narrative Update • Mar 22
IPCALAB: Upcoming Results Review And Margins Outlook Will Support Steady Fair Value
Analysts now set their fair value estimate for Ipca Laboratories at about ₹1,655, up from roughly ₹1,634. This reflects updated assumptions that include a slightly higher profit margin and P/E multiple, along with modest adjustments to projected revenue growth and an unchanged discount rate.Narrative Update • Mar 07
IPCALAB: Upcoming Results And Revised Assumptions Will Shape Future Earnings Visibility
Analysts have raised their fair value estimate for Ipca Laboratories from ₹1,106 to about ₹1,416, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E that they consider to more accurately capture the company’s earnings potential. What's in the News A board meeting is scheduled for February 13, 2026, to review and take on record the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (Key Developments).Recent updates
Narrative Update • May 06
IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility
Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).Narrative Update • Apr 19
IPCALAB: Upcoming Results And Revised Assumptions Will Guide Earnings Visibility
Analysts have trimmed their fair value estimate for Ipca Laboratories slightly from about ₹1,416 to around ₹1,407, reflecting updated assumptions on future revenue growth, profit margins and a modestly lower future P/E multiple. What's in the News Board meeting scheduled on February 13, 2026, to consider and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Narrative Update • Apr 05
IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value
Analysts have kept their fair value estimate for Ipca Laboratories steady at ₹1,655, reflecting unchanged assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for February 13, 2026 to consider and record the standalone unaudited financial results for the third quarter ended December 31, 2025 (Key Developments).Narrative Update • Mar 22
IPCALAB: Upcoming Results Review And Margins Outlook Will Support Steady Fair Value
Analysts now set their fair value estimate for Ipca Laboratories at about ₹1,655, up from roughly ₹1,634. This reflects updated assumptions that include a slightly higher profit margin and P/E multiple, along with modest adjustments to projected revenue growth and an unchanged discount rate.Narrative Update • Mar 07
IPCALAB: Upcoming Results And Revised Assumptions Will Shape Future Earnings Visibility
Analysts have raised their fair value estimate for Ipca Laboratories from ₹1,106 to about ₹1,416, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E that they consider to more accurately capture the company’s earnings potential. What's in the News A board meeting is scheduled for February 13, 2026, to review and take on record the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (Key Developments).Narrative Update • Feb 20
IPCALAB: Upcoming Board Results Review Will Support Upbeat Long Term Outlook
Analysts have nudged their fair value estimate for Ipca Laboratories up from about ₹1,565 to roughly ₹1,634, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board meeting scheduled for February 13, 2026, to review and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025.Analysis Article • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...Analysis Article • Feb 12
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Feb 06
IPCALAB: Upcoming Results Review Will Support Measured Outlook And Modest Assumption Shifts
Analysts have nudged their price target for Ipca Laboratories slightly higher, citing modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and record standalone unaudited financial results for the third quarter ended December 31, 2025.
Narrative Update • Jan 23
IPCALAB: Firmer Margins And Tighter P E Will Support Future Upside Potential
Analysts have inched up their fair value estimate for Ipca Laboratories to ₹1,731 per share from ₹1,730 per share, citing updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple in their models. What's in the News Board meeting scheduled for February 13, 2026, to consider and record standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Analysis Article • Jan 21
Ipca Laboratories Limited's (NSE:IPCALAB) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 45.1x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Narrative Update • Jan 08
IPCALAB: Board Meeting Schedule And Stable Assumptions Will Shape Balanced Outlook
Analysts have slightly raised their price target on Ipca Laboratories to ₹1,555 from ₹1,552, citing small adjustments to long term assumptions on revenue growth, profit margin and future P/E multiples. What's in the News Board meeting scheduled on Oct 17, 2025, at 17:00 Indian Standard Time (company filing) Board meeting set for Nov 13, 2025, to consider and record Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended Sep 30, 2025 (company filing) Valuation Changes Fair Value: The analyst fair value estimate has moved marginally higher from ₹1,551.82 to ₹1,555.06 per share.Narrative Update • Dec 24
IPCALAB: Improved Margins And Lower Multiple Will Support Future Upside Potential
Analysts have trimmed their price target on Ipca Laboratories by approximately ₹80 to around ₹1,730, reflecting slightly softer revenue growth assumptions, while still factoring in improved profit margins and a lower future P/E multiple. What's in the News Board meeting scheduled on October 17, 2025, at 17:00 IST to discuss corporate matters and ongoing strategic priorities (company filing).Narrative Update • Dec 10
IPCALAB: Biosimilar Partnership And Board Meetings Will Shape Balanced Outlook
Analysts have nudged their price target for Ipca Laboratories slightly higher to approximately ₹1,552 from about ₹1,543, reflecting modestly improved valuation multiples, even though there were only minor trims to long term revenue growth and profit margin assumptions. What's in the News Ipca Laboratories and BioSimilar Sciences PR LLC entered a Technology Transfer and Joint Development Agreement to shift late stage development, clinical manufacturing, and commercial supply of a next generation anti cancer or anti inflammatory monoclonal antibody biosimilar to BSS sterile campus in Aguadilla, Puerto Rico (company announcement) A board meeting is scheduled on October 17, 2025, at 17:00 Indian Standard Time to review corporate matters (company filing) A board meeting is set for November 13, 2025, to consider and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value Estimate has risen slightly from around ₹1,543 to about ₹1,552, reflecting a modestly higher intrinsic value.Analysis Article • Dec 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative Update • Nov 26
IPCALAB: Technology Partnership and Upcoming Board Meetings Will Influence Outlook
Narrative Update on Ipca Laboratories Analysts have raised their price target for Ipca Laboratories from ₹1,529.94 to ₹1,542.56. This change reflects optimism due to improved forecasts for revenue growth and profit margins.Narrative Update • Nov 11
IPCALAB: Technology Agreement With BioSimilar Sciences Will Drive Future Expansion
Analysts have raised their price target for Ipca Laboratories from ₹1,501.41 to ₹1,529.94, citing updated model assumptions and slight adjustments to long-term growth and margin forecasts. What's in the News Ipca Laboratories held a Board Meeting on October 17, 2025, at 17:00 Indian Standard Time.Analysis Article • Oct 19
Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Ipca...Analysis Article • Sep 05
If EPS Growth Is Important To You, Ipca Laboratories (NSE:IPCALAB) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Aug 15
The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
NSEI:IPCALAB 1 Year Share Price vs Fair Value Explore Ipca Laboratories's Fair Values from the Community and select...Analysis Article • Jul 08
Ipca Laboratories (NSE:IPCALAB) Will Pay A Dividend Of ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...Analysis Article • Jun 24
Ipca Laboratories' (NSE:IPCALAB) Dividend Will Be ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...Analysis Article • Jun 01
Ipca Laboratories Limited Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Ipca Laboratories Limited ( NSE:IPCALAB ) released its yearly result to the market...Analysis Article • May 22
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 51.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Analysis Article • Feb 16
Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders might have noticed that Ipca Laboratories Limited ( NSE:IPCALAB ) filed its third-quarter result this time...Analysis Article • Jan 10
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Dec 20
Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
With a price-to-earnings (or "P/E") ratio of 61.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...
New Narrative • Dec 12
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.Analysis Article • Nov 17
Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
The board of Ipca Laboratories Limited ( NSE:IPCALAB ) has announced that it will pay a dividend of ₹2.00 per share on...Analysis Article • Sep 10
Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Ipca Laboratories Limited's ( NSE:IPCALAB ) price-to-earnings (or "P/E") ratio of 61.7x might make it look like a...Analysis Article • Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Ipca Laboratories Limited ( NSE:IPCALAB ) recently...Analysis Article • May 24
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 31x, you may consider Ipca...Analysis Article • Feb 07
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
With a price-to-earnings (or "P/E") ratio of 61.8x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Analysis Article • Jan 09
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 20
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Feb 28
Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Sep 20
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 31
Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Today we will run through one way of estimating the intrinsic value of Ipca Laboratories Limited ( NSE:IPCALAB ) by...Analysis Article • Jun 22
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Shareholder Returns
| IPCALAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.2% | -0.07% | 0.5% |
| 1Y | 9.7% | 10.3% | -0.5% |
Return vs Industry: IPCALAB underperformed the Indian Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: IPCALAB exceeded the Indian Market which returned 0% over the past year.
Price Volatility
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: IPCALAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: IPCALAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 16,778 | Pranay Godha | www.ipca.com |
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology.
Ipca Laboratories Limited Fundamentals Summary
| IPCALAB fundamental statistics | |
|---|---|
| Market cap | ₹406.46b |
| Earnings (TTM) | ₹9.10b |
| Revenue (TTM) | ₹95.06b |
44.7x
P/E Ratio4.3x
P/S RatioIs IPCALAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPCALAB income statement (TTM) | |
|---|---|
| Revenue | ₹95.06b |
| Cost of Revenue | ₹31.42b |
| Gross Profit | ₹63.64b |
| Other Expenses | ₹54.54b |
| Earnings | ₹9.10b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 29, 2026
| Earnings per share (EPS) | 35.86 |
| Gross Margin | 66.94% |
| Net Profit Margin | 9.57% |
| Debt/Equity Ratio | 14.4% |
How did IPCALAB perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield6%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 23:22 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ipca Laboratories Limited is covered by 43 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Aditya Khemka | Ambit Capital |
| Sanjeev Chiniwar | Anand Rathi Shares and Stock Brokers Limited |